Frank Medici Sells 700 Shares of HealthEquity, Inc. (HQY) Stock

HealthEquity, Inc. (NASDAQ:HQY) Director Frank Medici sold 700 shares of HealthEquity stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $51.05, for a total value of $35,735.00. Following the sale, the director now directly owns 6,381 shares of the company’s stock, valued at approximately $325,750.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Frank Medici also recently made the following trade(s):

  • On Friday, November 3rd, Frank Medici sold 32,404 shares of HealthEquity stock. The stock was sold at an average price of $51.09, for a total value of $1,655,520.36.
  • On Monday, November 6th, Frank Medici sold 419,504 shares of HealthEquity stock. The shares were sold at an average price of $52.97, for a total value of $22,221,126.88.
  • On Tuesday, October 24th, Frank Medici sold 7,900 shares of HealthEquity stock. The shares were sold at an average price of $51.11, for a total value of $403,769.00.
  • On Monday, October 9th, Frank Medici sold 316,644 shares of HealthEquity stock. The shares were sold at an average price of $51.96, for a total value of $16,452,822.24.

Shares of HealthEquity, Inc. (HQY) traded down $0.57 during trading hours on Friday, reaching $50.17. The company’s stock had a trading volume of 238,743 shares, compared to its average volume of 460,806. The stock has a market cap of $3,034.73, a PE ratio of 79.63, a P/E/G ratio of 2.20 and a beta of 1.77. HealthEquity, Inc. has a 12 month low of $37.62 and a 12 month high of $55.31.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings results on Tuesday, September 5th. The company reported $0.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.13. HealthEquity had a return on equity of 13.93% and a net margin of 20.27%. The business had revenue of $56.90 million for the quarter, compared to analyst estimates of $55.66 million. During the same quarter in the prior year, the company posted $0.16 EPS. The company’s quarterly revenue was up 28.7% on a year-over-year basis. equities analysts predict that HealthEquity, Inc. will post 0.7 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.chaffeybreeze.com/2017/11/19/frank-medici-sells-700-shares-of-healthequity-inc-hqy-stock.html.

Several institutional investors have recently made changes to their positions in HQY. Zions Bancorporation acquired a new position in shares of HealthEquity in the 3rd quarter valued at $119,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of HealthEquity by 105.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,544 shares of the company’s stock valued at $127,000 after purchasing an additional 1,308 shares during the last quarter. Riverhead Capital Management LLC lifted its stake in shares of HealthEquity by 75.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,629 shares of the company’s stock valued at $131,000 after purchasing an additional 1,129 shares during the last quarter. Exane Derivatives acquired a new position in shares of HealthEquity in the 2nd quarter valued at $132,000. Finally, Oppenheimer Asset Management Inc. lifted its stake in shares of HealthEquity by 7.7% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 2,686 shares of the company’s stock valued at $134,000 after purchasing an additional 191 shares during the last quarter. 91.75% of the stock is currently owned by institutional investors and hedge funds.

Several analysts recently commented on the company. BidaskClub cut HealthEquity from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Zacks Investment Research cut HealthEquity from a “buy” rating to a “hold” rating in a research report on Wednesday. TheStreet upgraded HealthEquity from a “c” rating to a “b” rating in a research report on Monday, July 31st. Cantor Fitzgerald reiterated a “buy” rating and set a $56.00 price target on shares of HealthEquity in a research report on Tuesday, September 5th. Finally, Robert W. Baird reiterated a “hold” rating on shares of HealthEquity in a research report on Thursday, September 21st. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $57.50.

HealthEquity Company Profile

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Insider Buying and Selling by Quarter for HealthEquity (NASDAQ:HQY)

Receive News & Ratings for HealthEquity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply